The Outback Trial: A phase III trial of adjuvant chemotherapy following chemoradiation as a primary treatment for locally advanced cervical cancer compared to chemoradiation alone.
The purpose of this study is to compare standard treatment, radiation therapy combined with the chemotherapy drug cisplatin (chemo-radiation), to standard chemo-radiation therapy plus additional experimental chemotherapy with FDA approved agents carboplatin and paclitaxel to see if it reduces the risk of tumor recurrence and improves overall survival.
- Have locally advanced cervical cancer suitable for primary treatment with chemo-radiation with curative intent
- Be 18 years of age or older
- Be diagnosed with Stage IB2, II, IIIB, or IVA disease
- Have a performance status of 0-2
- Have Histological diagnosis of: squamous cell carcinoma, adenocarsinoma, or adenosquamous cell carcinoma of the cervix
- Have Adequate renal function
Clinical Research Coordinator